RxDoctor Payments Data

Christopher Polk, MD

Infectious Disease · Charlotte, NCNPI 1396889333

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,625 of the $8,818 with a category attached, or 75.1%. Viiv Healthcare Company accounts for 70.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $6,118 and has fallen 97.3% since, to $164 in 2025.

$8,818in general payments, 2019–2025

Across 27 payments — averaging $326.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$6K
  • Gilead$2K
  • Insmed, Inc.$291
  • Melinta Therapeutics, LLC$118
  • Merck$11
$830,036in research payments, 2019–2025

Across 207 payments — averaging $4009.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$242K
  • Regeneron$242K
  • Gilead$181K
  • Merck$131K
  • Melinta Therapeutics, LLC$23K
  • Pfizer$11K
  • plus $972 from 1 others

What the payments were for

  • Consulting fees$6,62575%
  • Travel & lodging$1,18313%
  • Food & beverage$7859%
  • Education$2253%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company15$6,179
Gilead4$2,219
Insmed, Inc.6$291
Melinta Therapeutics, LLC1$118
Merck1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,818 in reported general payments places this provider in the 85th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,848
Medicare patients
23
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala209$890,761
DovatoDolutegravir Sodium/Lamivudine199$632,423
OdefseyEmtricitab/Rilpiviri/Tenof Ala83$300,792
RukobiaFostemsavir Tromethamine29$271,848
CabenuvaCabotegravir/Rilpivirine29$188,831
TriumeqAbacavir/Dolutegravir/Lamivudi41$172,671
JulucaDolutegravir/Rilpivirine38$136,425
GenvoyaElviteg/Cob/Emtri/Tenof Alafen24$97,661
PrezcobixDarunavir/Cobicistat22$61,417
TivicayDolutegravir Sodium21$45,829
DescovyEmtricitabine/Tenofov Alafenam14$31,031
Abacavir-LamivudineAbacavir Sulfate/Lamivudine12$4,422
ValacyclovirValacyclovir Hcl17$923
Ondansetron Hcl14$246
Nevirapine12$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Rukobia, Cabenuva, Triumeq, Juluca$6,179$1,448,029357 claims
GileadBiktarvy, Genvoya, Descovy$2,219$1,019,452247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →